BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27686001)

  • 1. Aberrant DNA methylations in chondrosarcoma.
    Liu P; Shen JK; Xu J; Trahan CA; Hornicek FJ; Duan Z
    Epigenomics; 2016 Nov; 8(11):1519-1525. PubMed ID: 27686001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberration of
    Liu P; Garbutt C; Hornicek FJ; Liu F; Duan Z
    Anticancer Res; 2017 Jun; 37(6):2939-2945. PubMed ID: 28551631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Abnormalities in Chondrosarcoma.
    Bereza M; Dembiński M; Zając AE; Piątkowski J; Dudzisz-Śledź M; Rutkowski P; Czarnecka AM
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma.
    Liu P; Shen JK; Hornicek FJ; Liu F; Duan Z
    Sci Rep; 2017 May; 7(1):1580. PubMed ID: 28484252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.
    Nazeri E; Gouran Savadkoohi M; Majidzadeh-A K; Esmaeili R
    Crit Rev Oncol Hematol; 2018 Nov; 131():102-109. PubMed ID: 30293700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma.
    Skipar P; Dey M; Piątkowski J; Sulejczak D; Rutkowski P; Czarnecka AM
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.
    Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1.
    Galoian K; Qureshi A; D'Ippolito G; Schiller PC; Molinari M; Johnstone AL; Brothers SP; Paz AC; Temple HT
    Int J Oncol; 2015 Aug; 47(2):465-72. PubMed ID: 26094604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors.
    Hamm CA; Stevens JW; Xie H; Vanin EF; Morcuende JA; Abdulkawy H; Seftor EA; Sredni ST; Bischof JM; Wang D; Malchenko S; Bonaldo Mde F; Casavant TL; Hendrix MJ; Soares MB
    BMC Cancer; 2010 Sep; 10():471. PubMed ID: 20809981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
    Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
    Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chondrosarcoma: biology, genetics, and epigenetics.
    Chow WA
    F1000Res; 2018; 7():. PubMed ID: 30519452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth.
    Bao X; Ren T; Huang Y; Sun K; Wang S; Liu K; Zheng B; Guo W
    Cell Death Dis; 2017 Feb; 8(2):e2605. PubMed ID: 28182000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of chondrosarcoma.
    Jeong W; Kim HJ
    J Clin Pathol; 2018 Jul; 71(7):579-583. PubMed ID: 29593061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection.
    Gutteridge A; Rathbone VM; Gibbons R; Bi M; Archard N; Davies KEJ; Brown J; Plagnol V; Pillay N; Amary F; O'Donnell P; Gupta M; Tirabosco R; Flanagan AM; Forshew T
    Cancer Med; 2017 Oct; 6(10):2194-2202. PubMed ID: 28834325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [I. Identification of a Possible Therapeutic Target for Chondrosarcoma with IDH Mutant Inhibitors].
    Nakagawa M; Nakatani F; Kitabayashi I
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):212-216. PubMed ID: 28400543
    [No Abstract]   [Full Text] [Related]  

  • 16. [Inflammation as molecular target in chondrosarcoma].
    Kalinski T
    Pathologe; 2014 Nov; 35 Suppl 2():249-53. PubMed ID: 25394974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
    Gao D; Herman JG; Guo M
    Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
    van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
    J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic changes in osteosarcoma.
    Cui J; Wang W; Li Z; Zhang Z; Wu B; Zeng L
    Bull Cancer; 2011 Jul; 98(7):E62-8. PubMed ID: 21708514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A.
    Hua G; Liu Y; Li X; Xu P; Luo Y
    Oncol Rep; 2014 Jun; 31(6):2727-34. PubMed ID: 24789077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.